Chickenpox

• 

  Subject Areas on Research

  • A pediatrician's personal reflections on varicella. 
  • Acute retinal necrosis after chickenpox in a patient with acquired immunodeficiency syndrome. 
  • Chronic immune-mediated thrombocytopenia after varicella infection. 
  • Decreasing rates of hospitalization for varicella among young adults. 
  • History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC). 
  • Increasing incidence of varicella hospitalizations in United States Army and Navy personnel: are today's teenagers more susceptible? Should recruits be vaccinated? 
  • Infection with varicella-zoster virus after marrow transplantation. 
  • Large injection site reactions after a second dose of varicella vaccine. 
  • Life-threatening dysrhythmias in varicella myocarditis. 
  • Modified varicella-like syndrome in children previously vaccinated with live attenuated measles, mumps, rubella and varicella vaccine. 
  • Modified varicella-like syndrome. 
  • Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. 
  • Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina. 
  • Perinatal cytomegalovirus and varicella zoster virus infections: epidemiology, prevention, and treatment. 
  • Perspective on live varicella vaccine. 
  • Postlicensure study of varicella vaccine effectiveness in a day-care setting. 
  • Purpura fulminans. 
  • Racial differences in herpes zoster and age at onset of varicella. 
  • The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. 
  • Vaccinations for pregnant women. 
  • Varicella during pregnancy. Maternal and fetal effects. 
  • Varicella in a susceptible pregnant woman. 
  • Varicella prevalence in day-care centers. 
  • Varicella susceptibility and vaccine use among young adults enlisting in the United States Navy. 
  • Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program. 
• 

  Keywords of People

  • Clements III, Dennis Alfred, Professor Emeritus of Pediatrics, Pediatrics, Primary Care Pediatrics